<DOC>
	<DOCNO>NCT02001389</DOCNO>
	<brief_summary>This open-label , single-arm , multiple ascend dose Phase I study assess dose- concentration-dependent displacement [ 18F ] MNI-659 [ PET tracer target phosphodiesterase 10 ( PDE10 ) ] EVP-6308 .</brief_summary>
	<brief_title>Study EVP-6308 Assess Dose- Concentration-dependent Displacement 18FMNI-659 EVP-6308</brief_title>
	<detailed_description />
	<criteria>â€¢ Healthy male female volunteer , 18 50 year age Clinically significant abnormality physical examination , medical history , ECG , vital sign , laboratory value , unstable medical psychiatric illness Any disorder may interfere drug absorption . Clinically significant allergy sensitivity medication Positive test human immunodeficiency virus ( HIV ) antibody , Hepatitis B surface antigen , Hepatitis C antibody . Pregnant breast feeding . History exposure radiation &gt; 15 mSv/year ( e.g. , occupational radiation therapy ) past year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Enzyme occupancy</keyword>
	<keyword>Positron emission tomography ( PET )</keyword>
	<keyword>Phosphodiesterase 10 inhibitor</keyword>
</DOC>